Join Argenx at the BofA Securities 2025 Health Care Conference: Key Insights and Innovations Await!

Argenx to Present at BofA Securities Health Care Conference

On May 13, 2025, Argenx, a leading company in immunology, will present at the BofA Securities 2025 Health Care Conference. The CEO, Tim Van Hauwermeiren, and his management team will share updates at 4:20 p.m. PT.

You can watch the live presentation on the Argenx investors page. If you miss it, a recorded version will be available for 30 days after the event.

About Argenx

Argenx focuses on improving the lives of people with severe autoimmune diseases. They collaborate with top researchers through their Immunology Innovation Program to develop new antibody-based treatments. Their standout product is the first approved neonatal Fc receptor (FcRn) blocker, showing promise across various serious autoimmune conditions.

Recent research indicates that autoimmune diseases are on the rise, affecting millions globally. A study published in the Journal of Autoimmunity notes the growing prevalence, with an estimated 50 million people in the U.S. alone battling these conditions.

As discussions about healthcare innovation grow, social media is buzzing with reactions to Argenx’s advancements. Many patients and advocates express hope, looking forward to new treatment options.

For further details on Argenx’s work, you can visit their website at argenx.com or connect with them on social media platforms like LinkedIn, Instagram, and Facebook.

Contacts

Media:
Ben Petok
bpetok@argenx.com

Investors:
Alexandra Roy
aroy@argenx.com

Argenx is dedicated to transforming the landscape of autoimmune disease treatment. Their ongoing research and development promise to bring hope and improved outcomes to many.

Source link

Brussels Stock Exchange:ARGX, argenx SE